Replimune Starts U.S. Sales of TUDRIQEV for Advanced Melanoma
Replimune Group said TUDRIQEV is now commercially available in the U.S. for adults with unresectable advanced cutaneous melanoma progressing after PD-1 therapy, under accelerated approval.